| Document |
Document Title |
|
JP3918953B2 |
PURPOSE: To provide a tunable bisconjugate that comprises two saccharides which contain a plurality of monosaccharide units, at least one unit being uronic acid, and a spacer, and the spacer links one saccharide to the other saccharide a...
|
|
JP2007106724A |
To provide an inhibitor for pancreatic cancer development containing a poory digestive neutral oligosaccharide as an effective component.This inhibitor for pancreatic cancer development contains a poorly digestive neutral oligosaccharide...
|
|
JP2007077121A |
To provide a means for preventing or normalizing the imbalance of a skin normal bacteria flora and maintaining the skin healthy.This skin normal bacteria flora-improving agent comprises a uronic acid residue-having xylo-oligosaccharide. ...
|
|
JP2007039341A |
To provide low-molecular fucoidan-derived low-molecular compounds causing little problems related to absorbency, antigenicity, uniformity, anticoagulation activity, etc., having a specified structure and functions and produced when fucoi...
|
|
JP3878239B2 |
To obtain a safe and stabilized preventive and therapeutic agent for circulatory system diseases for example hyperlipemia or arteriosclerosis by using a specific derivative prepared by treating alginic acid or its salt with cell bodies o...
|
|
JP2007022968A |
To provide a composition with high efficacy and high safety for ameliorating and preventing diarrhea.The invention relates to the ameliorating agent and diarrhea preventive comprising a xylooligosaccharide composition as active component...
|
|
JP3865411B2 |
PURPOSE: To obtain the subject new anti-endotoxin compound useful for treating activation through a lipopolysaccharide (LPS) which serves as a medium for septic shocks, viral infectious diseases, etc. CONSTITUTION: The objective compound...
|
|
JP3850908B2 |
To obtain a blood sugar value increase-suppressing agent suitable for preventing and curing of abnormal blood sugar value such as diabetes mellitus, containing an oligogalacturonic acid. This blood sugar value increase-suppressing agent ...
|
|
JP2006522772A |
Fused oxabicyclic aminoalcohols of formula (I) and (II) processes for their preparation and uses thereof as scaffolds for preparing libraries of compounds of formula (XXVII) and (XXVIII) wherein the meanings of RI, R2,R3,R4 and R5 are re...
|
|
JP2006265250A |
To provide a method for producing a composition having high antioxidizing activity from bamboo grass and/or bamboo leaves as raw material.The method comprises the following procedure: From a lower aliphatic alcohol extract liquid from ba...
|
|
JP2006265249A |
To provide a new flavonoid compound having high antioxidizing activity from bamboo grass and/or bamboo leaves as raw material, to provide a method for producing the same, and to provide an antioxidant comprising the same.The method compr...
|
|
JP3824319B2 |
To provide a composition for activating NKT cell, etc., having improved effect. The composition for activating NKT cell contains a sphingoglycolipid having a structure expressed by formula (1) (R1 is group expressed by formula (1-1); and...
|
|
JP2006213614A |
To provide a gluconic acid salt powder suitable for making pharmaceutical preparations and food processing.The gluconic acid salt powder has a specific surface area of 1-50 m2/g, an average particle diameter of 1-500 μm, and two or more...
|
|
JP2006518759A |
It is taught here that enkephalin peptides which are glycosylated with a disaccharide will be transported across the blood brain barrier and deliver analgesic effects superior to morphine when introduced into the bloodstream. Glycosylate...
|
|
JP3808082B2 |
To obtain a composition suitable for topical application to the skin or the scalp, containing, in a physiologically acceptable medium, at least one compound of a prescribed formula, and to provide a method for beauty treatment, comprisin...
|
|
JPWO2004105753A1 |
An object of the present invention is to provide an antidepressant or an antidepressant food or drink. In order to solve the problem, the present invention presents the present invention in formula (I) (wherein R1, R2, R3 and R4 represen...
|
|
JP3798425B2 |
The invention concerns a pharmaceutical preparation which contains one or several galacturonides as the active substance with a degree of polymerization of >/=2 and a degree of esterification of <20% optionally together with common pharm...
|
|
JP2006176442A |
To provide a new compound usable as an active ingredient of a composition capable of sterilizing equipment for medical care such as an endoscope, and having low smell; and to provide the composition containing the compound.The glycoconju...
|
|
JP2006516257A |
Method for the production of C-aryl glucoside SGLT2 inhibitors useful for the treatment of diabetes and related diseases. and intermediates thereof. The C-aryl glucosides may be complexed with amino acid complex forming reagents.
|
|
JP3790273B2 |
There is disclosed a method of manufacturing 4,5-dihydroxy-2-cyclopenten-1-one represented by the following formula Ä1Ü which is characterized in that at least one substance selected from the following (a), (b) and (c) is heated. (a): ...
|
|
JP2006516148A |
The present invention relates to a process for extracting 2-keto-L-gulonic acid (KGA) from a polar, preferably aqueous, solvent, preferably from a solvent which comprises a mixture of ascorbic acid and 2-keto-L-gulonic acid, by means of ...
|
|
JP2006151893A |
To provide a yeast-type growth inducing agent of a dimorphic fungus, having high safety and capable of being expected to have an enough effect of improving various symptoms of fungal infections.This yeast-type growth inducing agent of th...
|
|
JP2006515863A |
Compounds of the following structure: are useful as nucleic labeling compounds.
|
|
JP2006509027A |
Compounds of the formula (I) where Ar and R are as defined herein, possess antibacterial properties.
|
|
JP2006508048A |
The invention relates to a difluorinated gem compound having formula (I) wherein R<1> is a group comprising an alkyl chain that is substituted by at least one amine, amide or acid function, R<2> is a hydrogen atom H or a free or protecte...
|
|
JP2006056826A |
To develop a highly digestible substance as an active ingredient for a cosmetological food composition to be orally administered, particularly to be used for cosmetologically ameliorating the skin.A cosmetological food composition is pro...
|
|
JP2006505607A |
The invention relates to a method for producing 2-keto-L-gulonic acid-C4-C10 alkyl ester by esterifying 2-keto-L-gulonic acid (KGS) with an unsaturated, branched or unbranched C4-C10 alcohol. The inventive method is characterized by the ...
|
|
JP3735381B2 |
PURPOSE: To obtain a composition useful for treating viral diarrhea from which the majority of infants suffer and which is confirmed to kill infants in the case of a severe symptom, comprising one or more compositions containing sialic a...
|
|
JP3732871B2 |
PURPOSE: To obtain in high yield a sialo-composite carbohydrate useful as e.g. a medicine by making endoglycosidase act on a composite carbohydrate composed of a sialic acid-contg. sugar chain to directly transfer the sialosugar chain to...
|
|
JP2005538032A |
[Task] [Chemical 1] The present invention provides a novel compound multifluorescent natural dye derived from the marine organism Holothuria scabra, which has a Si-OR type (R is an organic moiety) chemical structure. The silicic acid mat...
|
|
JP3719207B2 |
To obtain a safe tonic made from a natural raw material that is very effective against thin hair and loss of hair caused by male alopecia and free from side effect. This tonic contains an acidic xylooligosaccharide having an uronic acid ...
|
|
JP3713530B2 |
To obtain an acidic glycide or an acidic glycide-related compound useful for a food material or food itself as a souring agent and a calcium carrier, etc., by reacting a glycide (except glucose) and/or a glycide-related compound with glu...
|
|
JP2005533057A |
The invention is directed to compounds of formula (I) wherein X is O or NH; R′ is a hydrocarbon chain; R3 and R4 are hydrogen, OH or a monosaccharide; R5 is hydrogen or a monosaccharide; Q′ is optionally present and may be a C1-10 hy...
|
|
JP2005530808A |
This invention relates to a new pharmaceutically useful compound which is a stoichiometrically 1:1 adduct of tramadol hydrochloride and topiramate, to the manufacture and use thereof.
|
|
JP2005263755A |
To provide a stable composition for bleaching, highly safe to a human body, and having excellent effects; and to provide an external preparation for the skin, containing the composition.The composition for the bleaching contains an acidi...
|
|
JP2005521645A |
An amphiphilic compound is provided capable of forming vesicles or liposomes, said amphiphilic compound having at least one headgroup containing a selectively cleavable group or moiety such as a residue of a choline or phenylalanine deri...
|
|
JP3668538B2 |
To obtain an active oxygen-eliminating agent excellent in an eliminating action on active oxygen generated in a living body, high in safety, and capable of being used for foods, cosmetics, etc. This active oxygen-eliminating agent compri...
|
|
JP2005511550A |
The invention relates to compounds having the following formula (I), in which: Ra represents a sugar moiety, an arylamino group, or an alkyl group comprising at least one amino group, Rb represents an halogen atom, an halogenoalkyl group...
|
|
JP2005510568A |
This invention is directed to compounds of the formula (I):and their pharmaceutically acceptable salts, wherein R<1>, R<2>, and R<3 >are as defined herein; intermediates for the synthesis of such compounds, pharmaceutical compositions co...
|
|
JP2005504017A |
The present invention relates to the use of a glycosidase inhibitor for the manufacture of a medicament for the treatment of a disease, wherein glycosidase enzymes hydrolyze glycoconjugates of a patient to reveal neutral glycan receptors...
|
|
JP2004536047A |
Crystalline complexes are obtained from a 1:1 or 2:1 mixtures of either the (D) or (L) enantiomer of natural amino acids and compounds of formulawhereinR<1>, R<2 >and R<2a >are independently hydrogen, OH, OR<5>, alkyl, -OCHF2, -OCF3, -SR...
|
|
JP2004534085A |
The invention relates to Siglec inhibitors that have an increased affinity for the receptor molecule. The Siglec inhibitors provided by the invention are preferably selective of a given Siglec molecule. The invention further relates to a...
|
|
JP2004300112A |
To provide a new sugar ester having a structure different from conventional sugar ester and provide a method for the production of the sugar ester.The sugar ester is expressed by general formula (I) (T is the central skeleton T of uronic...
|
|
JP2004527472A |
Tacrolimus derivatives having high levels of neurotrophic activity and low levels of immunosuppresive activity. These compounds are useful as neurotrophic agents, particularly, for preventing or treating neuronal injury/dysfunction.
|
|
JP2004526671A |
The present invention relates to radiopharmaceuticals for diagnostic and therapeutic applications, conjugates of antioxidants with metal chelating ligands, intermediate compounds, methods for producing such radiopharmaceuticals, ligands,...
|
|
JP3559063B2 |
|
|
JP3556690B2 |
|
|
JP2004524357A |
In accordance with the present invention, there is provided pregabalin lactose conjugate compounds. Also provided as part of the present invention is a novel method of central nervous system disorders or diseases including seizure disord...
|
|
JP2004523464A |
Hydrophilic transportable N-linked glycosyl dopaminergic prodrug compounds according to FORMULA V,wherein, Ring 1 comprises a cyclic or heterocyclic ring, or aryl or heteroaryl ring, all of said rings comprising 4 to 8 carbon atoms, amon...
|
|
JP3551384B2 |
The present invention relates to a peritoneal dialysis solution comprising at least one amino sugar in an effective amount sufficient to create an osmotic pressure to effect the removal of water by diffusion from the patient's blood acro...
|
